Document:

Exhibit 10.1

 

EXECUTION VERSION

 

PURCHASE AGREEMENT

 

THIS PURCHASE AGREEMENT
(this “Agreement”) is made as of the 13th day of September, 2012, by and among Response Genetics, Inc., a Delaware
corporation (the “Company”), and the investors set forth in Exhibit A hereto (each an “Investor”
and collectively, the “Investors”).

 

Recitals

 

A.           The
Company and each Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by the provisions of Regulation D (“Regulation D”), as promulgated by the U.S. Securities and Exchange
Commission (the “SEC”) under the Securities Act of 1933, as amended;

 

B.           Each
Investor wishes to purchase from the Company, and the Company wishes to sell and issue to each Investor, upon the terms and conditions
stated in this Agreement, the number of shares of the Company’s common stock, par value $0.01 per share (the “Common
Stock”), set forth opposite such Investor’s name on Exhibit A hereto (the “Shares”),
at a purchase price of $1.10 per share; and

 

C.           Contemporaneous
with the sale of the Common Stock, the parties hereto will execute and deliver a Registration Rights Agreement, in the form attached
hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company will agree to
provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder,
and applicable state securities laws.

 

In consideration of
the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto agree as follows:

 

1.          Definitions.
In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement, the following terms
shall have the meanings set forth below:

 

“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is
controlled by, or is under common control with, such Person.

 

“Business Day”
means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.

 

    	 

    	 

    

 

“Bylaws”
means the Amended and Restated Bylaws of the Company, effective as of July 2010.

 

“Certificate
of Incorporation” means the Certificate of Incorporation of the Company as filed with the Secretary of State of the State
of Delaware on September 23, 1999, as amended prior to the date hereof.

 

“Common Stock”
has the meaning ascribed to it in the recitals.

 

“Company”
has the meaning ascribed to it in the preambles.

 

“Company’s
Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company,
after due inquiry.

 

“Confidential
Information” means trade secrets, confidential information and know-how (including but not limited to ideas, formulae,
compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications,
support documentation, drawings, specifications, designs, business and marketing plans, and customer and supplier lists and related
information).

 

“Control”
(including the terms “controlling”, “controlled by” or “under common control with”)
means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise.

 

“DGCL”
means the Delaware General Corporation Law, as amended.

 

“Disclosure
Schedules” has the meaning ascribed to it in Section 4.

 

“Effective Date”
means the date on which the initial Registration Statement is declared effective by the SEC.

 

“Effectiveness
Deadline” means the date on which the initial Registration Statement is required to be declared effective by the SEC
under the terms of the Registration Rights Agreement.

 

“Environmental
Laws” has the meaning ascribed to it in Section 4.16.

 

“GAAP”
has the meaning ascribed to it in Section 4.18.

 

“GSK Investor”
means Glaxo Group Limited.

 

“Infringe”
has the meaning ascribed to it in Section 4.15(d).

 

    	-2-

    	 

    

 

“Intellectual
Property” means all of the following: (i) patents, patent applications, patent disclosures and inventions (whether or
not patentable and whether or not reduced to practice); (ii) trademarks, service marks, trade dress, trade names, corporate names,
logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing; (iii) copyrights and
copyrightable works; (iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary computer software
(including but not limited to data, data bases and documentation).

 

“Investor”
or “Investors” has the meaning ascribed to it in the preambles.

 

“Law”
means any foreign, federal, state or local law, statute, code, ordinance, rule or regulation of any government or governmental
or regulatory entity.

 

“License Agreements”
has the meaning ascribed to it in Section 4.15(b).

 

“Liens”
has the meaning ascribed to it in Section 4.4.

 

“Material
Adverse Effect” means an event, change or occurrence that, individually or together with any other event, change or occurrence,
has a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial or otherwise), business,
or prospects of the Company and its Subsidiaries taken as a whole, or (ii) the ability of the Company to perform its obligations
under the Transaction Documents, excluding, for purposes of each of (i) and (ii), any event, change or occurrence resulting from
the announcement or consummation of the transactions contemplated by the Transaction Documents.

 

“Nasdaq”
means The NASDAQ Capital Market.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Prohibited
Transaction” has the meaning ascribed to it in Section 5.11.

 

“Purchase Price”
means, with respect to each Investor, the purchase price set forth opposite such Investor’s name on Exhibit A hereto.

 

“Rule 144”
means Rule 144 promulgated by the SEC under the 1933 Act, as amended.

 

“Registration
Rights Agreement” has the meaning ascribed to it in the recitals.

 

“Registration
Statement” has the meaning set forth in the Registration Rights Agreement.

 

“Regulation
D” has the meaning ascribed to it in the recitals.

 

    	-3-

    	 

    

 

“SEC”
has the meaning ascribed to it in the recitals.

 

“SEC Filings”
has the meaning ascribed to it in Section 4.6.

 

“Shares”
has the meaning ascribed to it in the recitals.

 

“Subsidiary”
of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests
of which is sufficient to elect at least a majority of its Board of Directors or other governing body (or, if there are no such
voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by such first Person.

 

“Trading Affiliates”
has the meaning ascribed to it in Section 5.11.

 

“Transaction
Documents” means this Agreement, the Registration Rights Agreement and any related agreements required to evidence the
transactions contemplated hereby.

 

“Transfer
Agent” has the meaning set forth in Section 6.6.

 

“1933 Act”
means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

 

2.          Purchase
and Sale of the Shares. Subject to the terms and conditions of this Agreement, at the Closing (as defined below), each Investor
severally shall purchase, and the Company shall sell and issue to each Investor, the number of Shares set forth opposite such Investor’s
name on Exhibit A hereto, in exchange for the Purchase Price for such Shares as specified in Section 3 below.

 

3.          Closing.
The closing (the “Closing”) of the purchase and sale of the Shares shall take place on the date hereof at the
offices of Willkie Farr & Gallagher LLP, 787 Seventh Avenue, New York, New York 10019, or at such other location and on such
other date as the Company and each Investor shall mutually agree. At the Closing, the Company shall issue the Shares to be purchased
by each Investor and, in full consideration and exchange for such Shares, such Investor shall thereupon pay to the Company an amount
representing the Purchase Price for such Shares (payable by a wire transfer in same day funds to be sent to the account of the
Company as instructed in writing by the Company). Within five (5) Business Days of the Closing, the Company shall cause its Transfer
Agent to deliver to each Investor a certificate or certificates, registered in such name or names as such Investor may designate
evidencing the Shares issued to such Investor.

 

    	-4-

    	 

    

 

4.          Representations
and Warranties of the Company. The Company hereby represents and warrants to each Investor that, except as set forth in the
schedules delivered herewith (collectively, the “Disclosure Schedules”):

 

4. 1         Organization, Good Standing
and Qualification. Each of the Company and its Subsidiaries is a corporation duly organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business
as now conducted and to own its properties. Each of the Company and its Subsidiaries is duly qualified to do business as a foreign
corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property
makes such qualification or leasing necessary unless the failure to so qualify has not had and could not reasonably be expected
to have a Material Adverse Effect.

 

4.2           Authorization.
The Company has full power and authority and has taken all requisite action on the part of the Company, its officers, directors
and stockholders necessary for (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization
of the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance and delivery
of the Shares The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against
the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium
and similar laws of general applicability, relating to or affecting creditors’ rights generally.

 

4.3           Capitalization.
(a) Schedule 4.3(a) sets forth as of the date hereof (i) the authorized capital stock of the Company; (ii) the number of
shares of capital stock issued and outstanding; (iii) the number of shares of capital stock issuable pursuant to the Company’s
stock plans; and (iv) the number of shares of capital stock issuable and reserved for issuance pursuant to securities (other than
the Shares) exercisable for, or convertible into or exchangeable for any shares of capital stock of the Company. All of the issued
and outstanding shares of the Company’s capital stock have been duly authorized and validly issued and are fully paid, nonassessable
and free of pre-emptive rights. No Person is entitled to pre-emptive or similar statutory or contractual rights with respect to
any securities of the Company. Except as described on Schedule 4.3(a), there are no outstanding warrants, options, convertible
securities or other rights, agreements or arrangements of any character under which the Company or any of its Subsidiaries is or
may be obligated to issue any equity securities of any kind and except as contemplated by this Agreement, neither the Company nor
any of its Subsidiaries is currently in negotiations for the issuance of any equity securities of any kind. Except as described
on Schedule 4.3(a) and except for the Registration Rights Agreement, there are no voting agreements, buy-sell agreements,
option or right of first purchase agreements or other agreements of any kind among the Company and any of the securityholders of
the Company, or by or among securityholders of the Company, relating to the securities of the Company held by them. Except as provided
in Schedule 4.3(a) and the Registration Rights Agreement, no Person has the right to require the Company to register any
securities of the Company under the 1933 Act, whether on a demand basis or in connection with the registration of securities of
the Company for its own account or for the account of any other Person.

 

    	-5-

    	 

    

 

The issuance and sale
of the Shares hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other
than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding
security.

 

The Company does not
have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect giving any Person
the right to purchase any equity interest in the Company upon the occurrence of certain events.

 

(b) Except as set forth
on Schedule 4.3(b), the Company has no Subsidiaries and no interest or investments in any Person. All of the issued and
outstanding stock (or equivalent interests) of each Subsidiary set forth on Schedule 4.3(b) has been duly authorized and
validly issued, is fully paid and nonassessable and is owned by the Company free and clear of any Liens and there are no rights,
options or warrants outstanding or other agreements to acquire shares of stock (or equivalent interests) of such Subsidiary.

 

4.4           Valid
Issuance. The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be
validly issued, fully paid and nonassessable, and shall be free and clear of all liabilities, debts, obligations, encumbrances,
leases, indebtedness, liens, charges, security interests, and pledges, of whatever nature, whether fixed or contingent, disclosed
or undisclosed, foreseen or unforeseen (“Liens”) (other than those created by the Investors), except for restrictions
on transfer set forth in the Transaction Documents or imposed by applicable securities laws.

 

4.5           Consents.
Except as described on Schedule 4.5, the execution,
delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Shares require no
consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than filings that
have been made pursuant to applicable state securities laws and post-sale filings pursuant to applicable state and federal securities
laws which the Company undertakes to file within the applicable time periods. Subject to the accuracy of the representations and
warranties of each Investor set forth in Section 5 hereof, the Company has taken all action necessary to exempt (i) the
issuance and sale of the Shares, and (ii) the other transactions contemplated by the Transaction Documents from the provisions
of any anti-takeover, business combination or control share law or statute binding on the Company or to which the Company or any
of its assets and properties may be subject and any anti-takeover provision of the Certificate of Incorporation or Bylaws that
is or could reasonably be expected to become applicable to any Investor as a result of the transactions contemplated hereby, including
without limitation, the issuance of the Shares and the ownership, disposition or voting of the Shares by any Investor or the exercise
of any right granted to any Investor pursuant to this Agreement or the other Transaction Documents.
Without limitation of the foregoing, for purposes of Section 203(a)(1) of the DGCL, the Board of Directors of the Company has approved
the transaction resulting in each of the Investors becoming an Interested Stockholder (as defined in Section 203 of the DGCL).

 

    	-6-

    	 

    

 

4.6           Delivery
of SEC Filings; Business. The Company has made available to the Investor through the EDGAR system, true and complete copies
of the Company’s most recent Annual Report on Form 10-K and Amendment No. 1 thereto for the fiscal year ended December 31,
2011, and all other reports filed by the Company pursuant to the 1934 Act prior to the date hereof (collectively, the “SEC
Filings”). The SEC Filings are the only periodic reports required of the Company pursuant to the 1934 Act. None of the
Subsidiaries of the Company are required to file reports under the 1934 Act.

 

4.7           Use
of Proceeds. The net proceeds of the sale of the Shares hereunder shall be used by the Company for working capital and general
corporate purposes, including any potential acquisitions.

 

4.8           No
Material Adverse Change. Since December 31, 2011, except as identified and described in the SEC Filings
(excluding any disclosures set forth in any risk factors section or forward-looking statements contained therein), there
has not been:

 

(a)          any
change in the consolidated assets, liabilities, financial condition or operating results of the Company from that reflected in
the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, except
for changes in the ordinary course of business which have not had and could not reasonably be expected to have a Material Adverse
Effect, individually or in the aggregate;

 

(b)          any
declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the
Company, or any redemption or repurchase of any securities of the Company;

 

(c)          any
material damage, destruction or loss, whether or not covered by insurance to any assets or properties of the Company or its Subsidiaries;

 

(d)          any
waiver, not in the ordinary course of business, by the Company or any Subsidiary of a material right or of a material debt owed
to it;

 

(e)          any
change or amendment to the Company's Certificate of Incorporation or Bylaws, or material change to any material contract or arrangement
by which the Company or any Subsidiary is bound or to which any of their respective assets or properties is subject;

 

(f)          any
material labor difficulties or labor union organizing activities with respect to employees of the Company or any Subsidiary;

 

(g)          any
material transaction entered into by the Company or a Subsidiary other than in the ordinary course of business;

 

(h)          the
loss of the services of any key employee, or material change in the composition or duties of the senior management of the Company
or any Subsidiary;

 

(i)          any
incurrence of any Lien on any material assets of the Company or any of its Subsidiaries;

 

    	-7-

    	 

    

 

(j)          any
creation, incurrence or assumption, or agreement to create, incur or assume, any indebtedness for borrowed money in respect of
the Company or its Subsidiaries or any entry by the Company or any of its Subsidiaries into, as lessee, any capitalized lease obligations
(as defined in Statement of Financial Accounting Standards No. 13);

 

(k)          any
change in accounting methods, principles or practices by the Company or any of its Subsidiaries materially affecting the consolidated
assets, liabilities or results of operations of the Company, except insofar as may have been required by a change in GAAP; or

 

(l)          any
other event or condition of any character that has had or could reasonably be expected to have a Material Adverse Effect.

 

4.9           SEC
Filings; S-3 Eligibility.

 

(a)          At
the time of filing thereof, the SEC Filings complied as to form in all material respects with the requirements of the 1934 Act
and did not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements
made therein, in the light of the circumstances under which they were made, not misleading.

 

(b)          The
Company is eligible to use Form S-3 to register the Registrable Securities (as such term is defined in the Registration Rights
Agreement) for sale by each Investor as contemplated by the Registration Rights Agreement.

 

4.10         No
Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by the Company
and the issuance and sale of the Securities (a) will not conflict with or result in a breach or violation of any of the terms and
provisions of, or constitute a default (or an event which, with or without notice or lapse of time or both, would constitute a
default) under (i) the Certificate of Incorporation or the Bylaws, both as in effect on the date hereof (true and complete copies
of which have been made available to each Investor through the EDGAR system), (ii) any Law or any order of any governmental agency
or body or any court, domestic or foreign, having jurisdiction over the Company, any Subsidiary or any of their respective assets
or properties, or (iii) the terms, conditions or provisions of any contract, agreement or other instrument to which the Company
or any Subsidiary is a party or by which the Company or a Subsidiary is bound or to which any of their respective assets or properties
is subject, and (b) will not result in a right of termination, modification, cancellation or acceleration under such contracts,
agreements or other instrument, except, in the case of clause (a)(ii), (a)(iii) and (b) only, such breaches, violations, defaults
or rights that individually or in the aggregate would not cause a Material Adverse Effect.

 

    	-8-

    	 

    

 

4.11         Tax
Matters. The Company and each Subsidiary has timely prepared and filed all tax returns required to have been filed by the Company
or such Subsidiary with all appropriate governmental agencies and timely paid all taxes shown thereon or otherwise owed by it,
except as would not have a Material Adverse Effect. The charges, accruals and reserves on the books of the Company in respect of
taxes for all fiscal periods are adequate in all material respects, and there are no material unpaid assessments against the Company
or any Subsidiary. All taxes and other assessments and levies that the Company or any Subsidiary is required to withhold or to
collect for payment have been duly withheld and collected and paid to the proper governmental entity or third party when due. There
are no tax liens or claims pending or, to the Company’s Knowledge, threatened against the Company or any Subsidiary or any
of their respective assets or property. There are no outstanding tax sharing agreements or other such arrangements between the
Company and any Subsidiary or other corporation or entity.

 

4.12         Title
to Properties. The Company and each Subsidiary have good and marketable title to all real properties and all other properties
and assets owned by it, in each case free from Liens and defects that would materially affect the value thereof or materially interfere
with the use made or currently planned to be made thereof by them; and the Company and each Subsidiary holds any leased real or
personal property under valid and enforceable leases with no exceptions that would materially interfere with the use made or currently
planned to be made thereof by them.

 

4.13         Certificates,
Authorizations and Permits. The Company and each Subsidiary possess adequate certificates, authorizations or permits issued
by appropriate governmental agencies or bodies necessary to conduct the business now operated by it, except where the failure to
possess such certificates, authorizations or permits has not had and could not reasonably be expected to have a Material Adverse
Effect, and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any such certificate, authority or permit that, if determined adversely to the Company or such Subsidiary, could reasonably
be expected to have a Material Adverse Effect, individually or in the aggregate.

 

4.14         Labor
Matters.

 

(a)          Neither
the Company nor any of its Subsidiaries is a party to or bound by any collective bargaining agreements or other agreements with
labor organizations. Neither the Company nor any of its Subsidiaries has violated in any material respect any Laws, orders or contract
terms, affecting the collective bargaining rights of employees, labor organizations or any Laws or orders affecting employment
discrimination, equal opportunity employment, or employees’ health, safety, welfare, wages and hours.

 

(b)          (i)
There are no labor disputes existing, or to the Company's Knowledge, threatened, involving strikes, slow-downs, work stoppages,
job actions, disputes, lockouts or any other disruptions of or by the Company's or any of its Subsidiaries’ employees, (ii)
there are no unfair labor practices or petitions for election pending or, to the Company's Knowledge, threatened before the National
Labor Relations Board or any other federal, state or local labor commission relating to the Company's or any of its Subsidiaries’
employees, (iii) no demand for recognition or certification heretofore made by any labor organization or group of employees is
pending with respect to the Company or any of its Subsidiaries and (iv) to the Company's Knowledge, the Company and its Subsidiaries
enjoy good labor and employee relations with their respective employees and labor organizations.

 

    	-9-

    	 

    

 

(c)          The
Company and its Subsidiaries are, and at all times have been, in compliance in all material respects with all applicable laws respecting
employment (including, without limitation, laws relating to classification of employees and independent contractors) and employment
practices, terms and conditions of employment, wages and hours, and immigration and naturalization. There are no claims pending
against the Company or any of its Subsidiaries before the Equal Employment Opportunity Commission or any other administrative body
or in any court asserting any violation of Title VII of the Civil Rights Act of 1964, the Age Discrimination Act of 1967, 42 U.S.C.
§§ 1981 or 1983 or any other federal, state or local Law, statute or ordinance barring discrimination in employment.

 

(d)          Except
as disclosed in the SEC Filings, neither the Company nor any of its Subsidiaries is a party to, or bound by, any employment or
other contract or agreement that contains any severance, termination pay or change of control liability or obligation, including,
without limitation, any “excess parachute payment,” as defined in Section 280G(b) of the Internal Revenue Code.

 

(e)          Each
employee of the Company is a person who is either a United States citizen or a permanent resident entitled to work in the United
States. To the Company's Knowledge, the Company does not have any liability for the improper classification by the Company of such
employees as independent contractors or leased employees prior to the Closing. Response Genetics, Ltd., the Company’s sole
Subsidiary, has no employees.

 

4.15         Intellectual
Property.

 

(a)          All
Intellectual Property of the Company and its Subsidiaries is currently in compliance with all legal requirements (including, without
limitation, timely filings, proofs and payments of fees) and is valid and enforceable. No Intellectual Property of the Company
or its Subsidiaries which is necessary for the conduct of Company’s and each of its Subsidiaries’ respective businesses
as currently conducted or as currently proposed to be conducted has been or is now involved in any cancellation or litigation,
and, to the Company’s Knowledge, no such action is threatened. No patent of the Company or its Subsidiaries has been or is
now involved in any interference, reissue, re-examination, cancellation or opposition proceeding.

 

(b)          All
of the licenses and sublicenses and consent, royalty or other agreements concerning Intellectual Property which are necessary for
the conduct of the Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently
proposed to be conducted to which the Company or any Subsidiary is a party or by which any of their assets are bound (other than
 generally commercially available, non-custom, off-the-shelf software application programs having a retail acquisition price
of less than $10,000 per license) (collectively, “License Agreements”) are valid and binding obligations of
the Company or its Subsidiaries that are parties thereto and, to the Company’s Knowledge, the other parties thereto, enforceable
in accordance with their terms, except to the extent that enforcement thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally, and to
the Company’s Knowledge there exists no event or condition which will result in a material violation or breach of or constitute
(with or without due notice or lapse of time or both) a default by the Company or any of its Subsidiaries under any such License
Agreement.

 

    	-10-

    	 

    

 

(c)          The
Company and its Subsidiaries own or have the valid right to use all of the Intellectual Property that is necessary for the conduct
of the Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed
to be conducted and for the ownership, maintenance and operation of the Company’s and its Subsidiaries’ properties
and assets, free and clear of all liens, encumbrances, adverse claims or obligations to license all such owned Intellectual Property
and Confidential Information, other than licenses entered into in the ordinary course of the Company’s and its Subsidiaries’
businesses. To the Company’s Knowledge, the Company and its Subsidiaries have a valid and enforceable right to use all third
party Intellectual Property and Confidential Information used or held for use in the respective businesses of the Company and its
Subsidiaries.

 

(d)          To
the Company’s Knowledge, the conduct of the Company’s and its Subsidiaries’ businesses as currently conducted
does not infringe or otherwise impair or conflict with (collectively, “Infringe”) any Intellectual Property
rights of any third party or any confidentiality obligation owed to a third party, and, to the Company’s Knowledge, the Intellectual
Property and Confidential Information of the Company and its Subsidiaries which are necessary for the conduct of Company’s
and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted are not
being Infringed by any third party. There is no litigation or order pending or outstanding or, to the Company’s Knowledge,
threatened or imminent, that seeks to limit or challenge or that concerns the ownership, use, validity or enforceability of any
Intellectual Property or Confidential Information of the Company and its Subsidiaries and the Company’s and its Subsidiaries’
use of any Intellectual Property or Confidential Information owned by a third party, and, to the Company’s Knowledge, there
is no valid basis for the same.

 

(e)          The
consummation of the transactions contemplated hereby and by the other Transaction Documents will not result in the alteration,
loss, impairment of or restriction on the Company’s or any of its Subsidiaries’ ownership or right to use any of the
Intellectual Property or Confidential Information which is necessary for the conduct of Company’s and each of its Subsidiaries’
respective businesses as currently conducted or as currently proposed to be conducted.

 

(f)          The
Company and its Subsidiaries have taken reasonable steps to protect the Company’s and its Subsidiaries’ rights in their
Intellectual Property and Confidential Information. To the Company’s Knowledge, each employee, consultant and contractor
who has had access to Confidential Information which is necessary for the conduct of Company’s and each of its Subsidiaries’
respective businesses as currently conducted or as currently proposed to be conducted has agreed to maintain the confidentiality
of such Confidential Information. Except under confidentiality obligations, to the Company’s Knowledge, there has been no
material disclosure of any of the Company’s or its Subsidiaries’ Confidential Information to any third party.

 

    	-11-

    	 

    

 

4.16         Environmental
Matters. Neither the Company nor any Subsidiary is in violation of any statute, rule, regulation, decision or order of any
governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances
or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively,
“Environmental Laws”), owns or operates any real property contaminated with any substance that is subject to
any Environmental Laws, is liable for any off-site disposal or contamination pursuant to any Environmental Laws, or is subject
to any claim relating to any Environmental Laws, which violation, contamination, liability or claim has had or could reasonably
be expected to have a Material Adverse Effect, individually or in the aggregate; and there is no pending or, to the Company’s
Knowledge, threatened investigation that might lead to such a claim.

 

4.17         Litigation.
Except as described in the SEC Filings, there are no pending material actions, suits or proceedings against or affecting the Company,
its Subsidiaries or any of its or their properties; and to the Company’s Knowledge, no such actions, suits or proceedings
are threatened or contemplated,. Neither the Company nor any Subsidiary, nor, to the Company’s Knowledge, any director or
officer thereof, is or since September 1, 2007 has been the subject of any action involving a claim of violation of or liability
under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the Company’s Knowledge,
there is not pending or contemplated, any investigation by the SEC involving the Company or any current or former director or officer
of the Company. The SEC has not issued any stop order or other order suspending the effectiveness of any registration statement
filed by the Company or any Subsidiary under the 1933 Act or the 1934 Act.

 

4.18         Financial
Statements. The financial statements included in each SEC Filing present fairly, in all material respects, the consolidated
financial position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods
shown, and such financial statements have been prepared in conformity with United States generally accepted accounting principles
applied on a consistent basis (“GAAP”) (except as may be disclosed therein or in the notes thereto, and, in
the case of quarterly financial statements, as permitted by Form 10-Q under the 1934 Act). Except as set forth in the financial
statements of the Company included in the SEC Filings, neither the Company nor any of its Subsidiaries has incurred any liabilities,
contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past
practices since the date of such financial statements, none of which, individually or in the aggregate, have had or could reasonably
be expected to have a Material Adverse Effect.

 

4.19         Insurance
Coverage. The Company and each Subsidiary maintains in full force and effect insurance coverage that its Board of Directors
has determined is reasonable for the business being conducted and properties owned or leased by the Company and each Subsidiary,
and the Company reasonably believes such insurance coverage to be adequate against all liabilities, claims and risks against which
it is customary for comparably situated companies to insure.

 

    	-12-

    	 

    

 

4.20         Compliance
with Nasdaq Continued Listing Requirements. Except as described on Schedule 4.20, the Company is in compliance with
applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened
against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice
of, nor except as set forth on Schedule 4.20 to the Company’s Knowledge is there any basis for, the delisting of the
Common Stock from Nasdaq.

 

 

4.21         No
Directed Selling Efforts or General Solicitation. Neither the Company nor any Person acting on its behalf has conducted any
general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any
of the Shares.

 

4.22         No
Integrated Offering. Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf has, directly
or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security, under circumstances
that would adversely affect reliance by the Company on Section 4(a)(2) of the 1933 Act for the exemption from registration for
the transactions contemplated hereby or would require registration of the Shares under the 1933 Act.

 

4.23         Private
Placement. Subject to the accuracy of the representations and warranties of each Investor set forth in Section 5 hereof,
the offer and sale of the Shares to each Investor as contemplated hereby is exempt from the registration requirements of the 1933
Act.

 

4.24         Questionable
Payments. Neither the Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any of their
respective current or former stockholders, directors, officers, employees, agents or other Persons acting on behalf of the Company
or any Subsidiary, has on behalf of the Company or any Subsidiary or in connection with their respective businesses: (a) used any
corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b)
made any direct or indirect unlawful payments to any governmental officials or employees from corporate funds; (c) established
or maintained any unlawful or unrecorded fund of corporate monies or other assets; (d) made any false or fictitious entries on
the books and records of the Company or any Subsidiary; or (e) made any unlawful bribe, rebate, payoff, influence payment, kickback
or other unlawful payment of any nature.

 

4.25         Transactions
with Affiliates. Except as disclosed in the SEC Filings, none of the officers or directors of the Company and none of the employees
of the Company is presently a party to any transaction with the Company or any Subsidiary (other than as holders of stock options
and/or warrants, and for services as employees, officers and directors), including, without limitation, any contract, agreement
or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or
from, or otherwise requiring payments to or from any officer, director or such employee or, to the Company’s Knowledge, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

 

    	-13-

    	 

    

 

4.26         Internal
Controls. The Company is in material compliance with the provisions
of the Sarbanes-Oxley Act of 2002, as amended, currently applicable to the Company. The Company and the Subsidiaries maintain
a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance
with management's general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance
with management's general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure
controls and procedures (as defined in 1934 Act Rules 13a-15(e) and 15d-15(e)) for the Company and designed such disclosure controls
and procedures to ensure that material information relating to the Company, including the Subsidiaries, is made known to the certifying
officers by others within those entities, particularly during the period in which the Company’s most recently filed periodic
report under the 1934 Act, as the case may be, is being prepared. The Company's certifying officers have evaluated the effectiveness
of the Company's controls and procedures as of the end of the period covered by the most recently filed periodic report under the
1934 Act (such date, the "Evaluation Date"). The Company presented in its most recently filed periodic report
under the 1934 Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures
based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the
Company's internal controls (as such term is defined in Item 308 of Regulation S-K) or, to the Company's Knowledge, in other factors
that could reasonably be expected to significantly affect the Company's internal controls. The Company maintains and will continue
to maintain a standard system of accounting established and administered in accordance with GAAP and the applicable requirements
of the 1934 Act.

 

4.27         Compliance
with Laws. Except as set forth in the SEC Filings, neither the Company nor any of its Subsidiaries, is, or since September
1, 2007, has been, in violation of any Laws in any material respect or any order, decree or injunction applicable to the Company
or any of its Subsidiaries.

 

5.          Representations
and Warranties of Investors. Each Investor, severally and solely with respect to itself and not jointly, hereby represents
and warrants to the Company that:

 

5.1           Organization
and Existence. Such Investor is either an individual or a validly existing corporation, limited partnership or limited liability
company and has all requisite corporate, partnership or limited liability company power and authority to invest in the Shares to
be purchased by such Investor pursuant to this Agreement, and to enter into and to consummate the transactions contemplated by
the Transaction Documents and otherwise carry out its obligations hereunder and thereunder.

 

5.2           Authorization.
The execution, delivery and performance by the Investor of the Transaction Documents to which such Investor is a party have been
duly authorized and each will constitute the valid and legally binding obligation of such Investor, enforceable against the Investor
in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and
similar laws of general applicability, relating to or affecting creditors’ rights generally.

 

    	-14-

    	 

    

 

5.3           Purchase
Entirely for Own Account. The Shares to be received by such Investor hereunder will be acquired for such Investor’s own
account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933
Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in
violation of the 1933 Act without prejudice, however, to such Investor’s
right at all times to sell or otherwise dispose of all or any part of such Shares
in compliance with applicable federal and state securities Laws. Nothing
contained herein shall be deemed a representation or warranty by such Investor to hold the Shares
for any period of time. Such Investor is not a broker-dealer registered with the SEC under the 1934 Act or an entity engaged
in a business that would require it to be so registered.

 

5.4           Investment
Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Shares
to be purchased by such Investor and has such knowledge and experience in financial or business matters that it is capable of evaluating
the merits and risks of the investment contemplated hereby.

 

5.5           Disclosure
of Information. Such Investor has had an opportunity to receive all information related to the Company requested by it and
to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the
offering of the Shares. Such Investor acknowledges receipt of copies of the SEC Filings.

 

5.6           Restricted
Securities. Such Investor understands that the Shares are characterized as “restricted securities” under the U.S.
federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and
that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain
limited circumstances. In connection with any transfer of Shares to a transferee other than (i) pursuant to an effective registration
statement or Rule 144, (ii) to the Company or (iii) to an Affiliate of such Investor, such Investor understands that the Company
may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred Shares under the Securities Act. As a condition of transfer, such transferee
(other than under (i), (ii) or (iii) above) shall agree in writing to be bound by the terms of this Agreement and shall have the
rights of such Investor under this Agreement and the Registration Rights Agreement.

 

5.7           Legends.
It is understood that, except as provided below, certificates evidencing the Shares may bear the following or any similar legend:

 

    	-15-

    	 

    

 

(a)          “The
securities represented hereby have not been registered under the Securities Act of 1933, as amended, or any state securities laws.
The securities represented hereby may not be transferred unless (i) such securities have been registered for sale pursuant to the
Securities Act of 1933, as amended, (ii) such securities may be sold without restriction pursuant to Rule 144, or (iii) the Company
has received an opinion of counsel reasonably satisfactory to it that such transfer may lawfully be made without registration under
the Securities Act of 1933 or qualification under applicable state securities laws.”

 

(b)          If
required by the authorities of any state in connection with the issuance or sale of the Shares, the legend required by such state
authority.

 

5.8           Accredited
Investor. Such Investor is an accredited investor as defined in Rule 501(a) of Regulation D, as amended, under the 1933 Act.

 

5.9           No
General Solicitation. Such Investor did not learn of the investment in the Shares as a result of any general solicitation or
general advertising.

 

5.10         Prohibited
Transactions. Since the earlier of (a) such time as such Investor was first contacted by the Company or any other Person acting
on behalf of the Company regarding the transactions contemplated hereby or (b) thirty (30) days prior to the date hereof, neither
such Investor nor any Affiliate of such Investor which (x) had knowledge of the transactions contemplated hereby, (y) has or shares
discretion relating to such Investor’s investments or trading or information concerning such Investor’s investments,
including in respect of the Shares, or (z) is subject to such Investor’s review or input concerning such Affiliate’s
investments or trading (collectively, “Trading Affiliates”) has, directly or indirectly, effected or agreed
to effect any short sale, whether or not against the box, established any “put equivalent position” (as defined in
Rule 16a-1(h) under the 1934 Act) with respect to the Common Stock, granted any other right (including, without limitation, any
put or call option) with respect to the Common Stock or with respect to any security that includes, relates to or derived any significant
part of its value from the Common Stock or otherwise sought to hedge its position in the Shares (each, a “Prohibited Transaction”).
Prior to the earliest to occur of (i) the termination of this Agreement, (ii) the Effective Date or (iii) the Effectiveness Deadline,
such Investor shall not, and shall cause its Trading Affiliates not to, engage, directly or indirectly, in a Prohibited Transaction.

 

6.          Covenants
and Agreements of the Company.

 

6.1           No
Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment that would conflict
or interfere in any material respect with the Company’s obligations to each Investor under the Transaction Documents.

 

6.2           Insurance.
The Company shall not materially reduce the insurance coverages described in Section 4.19.

 

6.3           Compliance
with Laws. The Company will comply in all material respects with all applicable Laws, orders and decrees of all governmental
authorities.

 

    	-16-

    	 

    

 

6.4           Listing
of Underlying Shares and Related Matters. The Company shall take all necessary action to cause the Shares to be listed on Nasdaq
as soon as practicable on or after the Closing Date. Without limiting the generality of the foregoing, no later than five Business
Days after the Closing Date, the Company shall file with Nasdaq a Notification Form: Listing of Additional Shares for the listing
of the Shares on Nasdaq, a copy of which shall be provided to each Investor. Further, if the Company applies to have its Common
Stock or other securities traded on any other principal stock exchange or market, it shall include in such application the Shares
and will take such other action as is necessary to cause such Common Stock to be so listed. The Company will use commercially reasonable
efforts to continue the listing and trading of its Common Stock on Nasdaq and, in accordance therewith, will use commercially reasonable
efforts to comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of
such market or exchange, as applicable.

 

6.5           Termination
of Covenants. The provisions of Sections 6.1 through 6.4 shall terminate and be of no further force and effect
on the date on which the Company’s obligations under the Registration Rights Agreement to register or maintain the effectiveness
of any registration covering the Registrable Securities (as such term is defined in the Registration Rights Agreement) shall terminate.

 

6.6           Removal
of Legends. In connection with any sale or disposition of the Shares by any Investor pursuant to Rule 144 or pursuant to any
other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by such Investor
with the requirements of this Agreement, the Company shall cause the transfer agent for the Common Stock (the “Transfer
Agent”) to issue replacement certificates representing the Shares sold or disposed of without restrictive legends. Upon
the earlier of (i) registration for resale pursuant to the Registration Rights Agreement or (ii) the Shares becoming freely tradable
by a non-affiliate pursuant to Rule 144 the Company shall (A) deliver to the Transfer Agent irrevocable instructions that the Transfer
Agent shall reissue a certificate representing shares of Common Stock without legends upon receipt by such Transfer Agent of the
legended certificates for such shares, together with either (1) a customary representation by such Investor that Rule 144 applies
to the shares of Common Stock represented thereby or (2) a statement by such Investor that such Investor has sold the shares of
Common Stock represented thereby in accordance with the Plan of Distribution contained in the Registration Statement, and (B) cause
its counsel to deliver to the Transfer Agent one or more blanket opinions to the effect that the removal of such legends in such
circumstances may be effected under the 1933 Act. From and after the earlier of such dates, upon such Investor’s written
request, the Company shall promptly cause certificates evidencing such Investor’s Shares to be replaced with certificates
which do not bear such restrictive legends.

 

    	-17-

    	 

    

 

6.7           Board
Observer Rights. For so long as the GSK Investor or its Affiliates own at least 50% of the Shares set forth opposite the GSK
Investor’s name on Exhibit A hereto, the GSK Investor may from time to time by written notice to the Company designate
one (1) person as a non-voting observer to attend all meetings of the Board of Directors of the Company (the “Observer”),
which Observer may be removed and replaced at any time by the GSK Investor. During any period in which the GSK Investor has so
designated an Observer, the Company shall: (a) provide the Observer notice of all regular meetings and all special meetings of
the Board of Directors in the same manner and at the same time notice is provided to members of the Board of Directors provided
that the GSK Investor acknowledges that special meetings of the Board of Directors may be held with short notice from time to time
depending on the needs of the Company and the unavailability of the Observer to attend any such meetings shall not affect the scheduling
and/or proceeding of any such special meeting of the Board of Directors; (b) permit the Observer to attend such meetings as an
observer (either in person or by telephone, as applicable, and with respect to in person meetings, upon request by the Observer,
by telephone) provided that the Observer may be required by the Board of Directors to temporarily leave a meeting of the Board
of Directors (i) if the presence of the Observer at such time would reasonably be expected to prevent the Company from asserting
the attorney-client or attorney work product privilege with respect to matters discussed before the Board of Directors at such
time or (ii) if matters will be discussed or decided relating to transactions in which the GSK Investor or any Affiliate thereof
or the Observer has a material direct or indirect interest; and (c) provide to the Observer a copy of all materials made available
by the Company to the Board of Directors prior to or at such meetings or otherwise (provided that to the extent that the Company
determines that the GSK Investor, its Affiliates or the Observer have a conflict of interest with respect to the subject matter
of any such materials or such provision would reasonably be expected to prevent the Company from asserting the attorney-client
or attorney work product privilege, the Company may redact such information from the materials) contemporaneously with delivery
to the members of the Board of Directors, as applicable. The GSK Investor acknowledges and agrees that upon exercise of its rights
under this Section 6.7, the GSK Investor may receive material non-public “inside information” of the Company
or its Subsidiaries provided to the Observer either at any meeting of the Board of Directors that the Observer attends or furnished
to the Observer pursuant to this Section 6.7 as material distributed to the members of the Board of Directors. The GSK Investor
hereby agrees to comply with all applicable securities Laws with respect to any material non-public information obtained by the
Observer pursuant to the rights granted to the GSK Investor under this Section 6.7. The right of the GSK Investor to designate
an Observer under this Section 6.7 shall not in any way be limited, restricted or prohibited by the fact that an Observer
is not appointed as of the date hereof.

 

6.8           Opinion
of Counsel. On the Closing Date, the Company shall deliver to the Investors an opinion from Willkie Farr & Gallagher LLP,
the Company’s counsel, dated as of the Closing Date in the form attached hereto as Exhibit C.

 

7.          Survival
and Indemnification.

 

7.1           Survival.
Except as otherwise set forth herein, the representations, warranties, covenants and agreements contained in this Agreement shall
survive the Closing of the transactions contemplated by this Agreement for a period of one year.

 

7.2           Indemnification.
The Company agrees to indemnify and hold harmless each Investor and its Affiliates and their respective directors, officers, employees
and agents from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable
attorney fees and disbursements and other expenses incurred in connection with investigating, preparing or defending any action,
claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to
which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to
be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts
as they are incurred by such Person.

 

    	-18-

    	 

    

 

7.3           Conduct of Indemnification
Proceedings. Promptly after receipt by any Person (the “Indemnified Person”) of notice of
any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding or investigation
in respect of which indemnity may be sought pursuant to Section 7.2, such Indemnified Person shall promptly notify the Company
in writing and the Company shall assume the defense thereof, including, without limitation, the employment of counsel reasonably
satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses; provided, however,
that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its obligations hereunder
except to the extent that the Company is materially prejudiced by such failure to notify. In any such proceeding, any Indemnified
Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such
Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel;
or (ii) in the reasonable judgment of counsel to such Indemnified Person representation of both parties by the same counsel would
be inappropriate due to actual or potential differing interests between them. The Company shall not be liable for any settlement
of any proceeding effected without its written consent, which consent shall not be unreasonably withheld, but if settled with such
consent, or if there be a final judgment for the plaintiff, the Company shall indemnify and hold harmless such Indemnified Person
from and against any loss or liability (to the extent stated above) by reason of such settlement or judgment. Without the prior
written consent of the Indemnified Person, which consent shall not be unreasonably withheld, the Company shall not effect any settlement
of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnity
could have been sought hereunder by such Indemnified Party, unless such settlement includes an unconditional release of such Indemnified
Person from all liability arising out of such proceeding.

 

8.          Miscellaneous.

 

8.1           Successors
and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the Company or the Investors,
as applicable, provided, however, that an Investor may assign its rights and delegate its duties hereunder in whole or in part
to an Affiliate or to a third party acquiring some or all of its Shares in a transaction complying with applicable securities laws
without the prior written consent of the Company or the other Investors, provided further that the Company may assign its rights
and delegate its duties hereunder to any surviving or successor corporation in connection with a merger or consolidation of the
Company with another corporation, or a sale, transfer or other disposition of all or substantially all of the Company’s assets
to another corporation, without the prior written consent of any Investor
except as required by law. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective
permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.

 

    	-19-

    	 

    

 

8.2           Counterparts;
Faxes. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This Agreement may also be executed and transmitted via facsimile, or by
portable document format via electronic mail, which shall be deemed an original.

 

8.3           Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

 

8.4           Notices.
Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed
effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such
delivery, (ii) if given by telex or telecopier, then such notice shall be deemed given upon receipt of confirmation of complete
transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such notice by the
recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally
recognized overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier. All notices
shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate
by ten days’ advance written notice to the other party:

 

If to the Company:

 

Response Genetics, Inc.

1640 Marengo Street

6th Floor

Los Angeles, California 90033

Attention:  Thomas Bologna

Fax:             (323) 276-2296

 

With a copy to:

 

Willkie Farr & Gallagher LLP

787 Seventh Avenue

New York, New York 10019-6099

Attention:    Steven A. Seidman

                      Laura
L. Delanoy

		Fax:	(212) 728-9763

 

If to an Investor:

 

to the address of such Investor
set forth on Exhibit A hereto.

 

    	-20-

    	 

    

 

8.5           Expenses.
The parties hereto shall pay their own costs and expenses in connection herewith; it being understood that each of the Company
and Investors has relied for such matters on the advice of its own respective counsel.

 

8.6           Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company
and the affected Investor; provided, however, that no such amendment or waiver which adversely affects any Investor shall be binding
on such Investor without its written consent. Any amendment or waiver effected in accordance with this Section 8.6 shall
be binding upon each holder of any Shares purchased under this Agreement at the time outstanding, each future holder of all such
Shares, and the Company.

 

8.7           Publicity.
Except as set forth below, no public release or announcement concerning the transactions contemplated hereby shall be issued by
the Company or any Investor without the prior consent of the Company (in the case of a release or announcement by any Investor)
or each Investor (in the case of a release or announcement by the Company) (which consents shall not be unreasonably withheld),
except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange
or securities market, in which case (and with respect to each filing and press release described in this Section 8.7) the
Company or any Investor, as the case may be, shall allow such Investor or the Company, as applicable, to the extent reasonably
practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. By 8:30
a.m. (New York City time) on the trading day immediately following the Closing Date, the Company shall issue a press release disclosing
the consummation of the transactions contemplated by this Agreement in the form set forth in Exhibit D. Promptly following
the Closing Date, the GSK Investor shall issue a press release with respect to the transactions contemplated by this Agreement
in substantially the form set forth in Exhibit E. No later than the fourth trading day following the Closing Date, the Company
will file a Current Report on Form 8-K attaching the press release issued by the Company as well as copies of the Transaction Documents.
In addition, the Company will make such other filings and notices in the manner and time required by the SEC or Nasdaq.

 

8.8           Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted
as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted
by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable
in any respect.

 

8.9           Entire
Agreement. This Agreement, including the Exhibits and the Disclosure Schedules, and the other Transaction Documents constitute
the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements
and understandings, both oral and written, among the parties with respect to the subject matter hereof and thereof.

 

    	-21-

    	 

    

 

8.10         Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions
as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements
herein contained.

 

8.11         Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with,
the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably
submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District
Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising
out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or
proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices
under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action
or proceeding and to the laying of venue in such court. Each of the parties hereto irrevocably waives any objection to the laying
of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action
or proceeding brought in any such court has been brought in an inconvenient forum.  EACH OF THE PARTIES HERETO WAIVES ANY RIGHT
TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY
AS TO THIS WAIVER.

 

[Signature pages follow]

 

    	-22-

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first
above written.

 

	The Company:	RESPONSE GENETICS, INC.
	 	 
	 	By:	/s/ Thomas A. Bologna
	 	Name:  Thomas A. Bologna
	 	Title:    Chairman & Chief Executive Officer

 

[Signature Page – Purchase Agreement]

 

    	 

    	 

    

 

	 Investor: 	GLAXO GROUP LIMITED
	 	 
	 	By:	/s/ Paul Williamson
	 	Name: Paul Williamson
	 	Title:   Authorized Signatory
	 	For and on behalf of
	 	The Wellcome Foundation Limited
	 	Corporate Director

 

[Signature Page – Purchase Agreement]

 

    	 

    	 

    

 

	Investor:	SWIFTCURRENT PARTNERS L.P.
	 	 
	 	 
	 	By:	/s/ Michael Tierney
	 	Name: Michael Tierney
	 	Title:   Chief Financial Officer,
	 	Bridger Management LLC,
	 	Investment Advisor to Swiftcurrent Partners, L.P.
	 	 
	 	SWIFTCURRENT OFFSHORE, LTD.
	 	 
	 	By:	/s/ Michael Tierney
	 	Name: Michael Tierney
	 	Title:   Chief Financial Officer,
	 	Bridger Management LLC,
	 	Investment Advisor to Swiftcurrent Offshore, Ltd.

 

[Signature Page – Purchase Agreement]

 

    	 

    	 

    

 

EXHIBIT A

 

Investors; Notice Address; Shares; and Purchase
Price

 

	Investors and Notice
 Address	 	Shares	 	 	Price Per Share	 	 	Purchase Price	 
	Glaxo Group Limited  

 Glaxo Wellcome House 

Berkeley Avenue

 Greenford 

Middlesex

 UB6 0NN

 England	 	 	5,000,000	 	 	$	1.10	 	 	$	5,500,000	 
	Swiftcurrent
Partners, L.P.

c/o Bridger Capital LLC

90 Park Avenue, 40th Fl. 

New York, NY 10016
	 	 	1,424,000	 	 	$	1.10	 	 	$	1,566,400	 
	Swiftcurrent
Offshore, Ltd.

c/o Bridger Capital LLC

90 Park Avenue, 40th Fl. 

New York, NY 10016
	 	 	1,576,000	 	 	$	1.10	 	 	$	1,733,600	 

 

    	 

    	 

    

 

EXHIBIT B

 

FORM OF REGISTRATION RIGHTS AGREEMENT

 

Please see Exhibit  10.2 of the 8-K
filed herewith which sets forth the Registration Rights Agreement.

 

    	 

    	 

    

 

EXHIBIT C

 

FORM OF OPINION OF WILLKIE FARR &
GALLAGHER LLP

   

 

1.          The
Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has
the requisite corporate power and authority to carry on its business as now conducted and to own its properties.

 

2.          The
Company has the corporate power and authority and has taken all requisite corporate action necessary for (i) the authorization,
execution and delivery of the Transaction Documents, (ii) the authorization of the performance of all obligations of the Company
under the Transaction Documents, and (iii) the authorization, issuance and delivery of the Shares. The Transaction Documents constitute
the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject
to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating
to or affecting creditors’ rights generally.

 

3.          The
Shares have been duly authorized and, when issued, sold and delivered against payment therefor in accordance with the provisions
of the Agreement, will be duly and validly issued, fully paid and non-assessable and free of any preemptive rights under the statutory
provisions of the DGCL, the Company’s Certificate of Incorporation or By-laws, each as amended to date, or any Material Agreement
(as defined in Paragraph 6 below).

 

4.          To
our knowledge, no Person is entitled to any preemptive right, right of first refusal or similar rights with respect to the issuance
of the Shares.

 

5.          The
execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Shares
require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official known to
us other than those that have been made or obtained which are in full force and effect and post-sale filings pursuant to applicable
state and federal securities laws.

 

6.          The
execution, delivery and performance of the Transaction Documents by the Company and the issuance and sale of the Shares do not
and will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under
(i) the Company’s Certificate of Incorporation or Bylaws, each as amended to date, (ii) any statute, rule, regulation or
order of any governmental agency or body or any court, domestic or foreign, known to us and having jurisdiction over the Company,
any Subsidiary or any of their respective assets or properties or (iii) any of the material contracts, instruments or arrangements
by which the Company or any Subsidiary is bound or to which any of their respective assets or properties is subject, as of the
date hereof (“Material Agreements”), each of which is set forth in Annex I hereto.

 

7.          Assuming
the representations made by the Investors in the Transaction Documents are true and correct, the initial sale of the Shares as
contemplated by the Transaction Documents is exempt from the registration and prospectus delivery requirements of the 1933 Act.

  

    	 

    	 

    

    

EXHIBIT D

 

COMPANY PRESS RELEASE

  

FOR IMMEDIATE RELEASE

 

	Investor Relations Contact:	Company Contact:
	Peter Rahmer	Thomas A. Bologna
	Trout Group	Response Genetics, Inc.
	646-378-2973	323-276-6060

 

Response
Genetics Raises $8.8 Million in Financing

 

Company to Present at UBS Global Life
Sciences in NYC on September 20, 2012

 

LOS
ANGELES, September 13, 2012 – Response Genetics, Inc. (Nasdaq: RGDX) announced
today that it has entered into a purchase agreement with GlaxoSmithKline and one of its existing significant stockholders to raise
$8.8 million from the private placement of 8,000,000 newly issued shares of its common stock at a purchase price of $1.10 per share.

 

The signing of the purchase
agreement and closing of the financing occurred today, Thursday, September 13, 2012.

 

“We are pleased to welcome GlaxoSmithKline as a new investor,
given our long standing relationship,” said Thomas Bologna, chairman and chief executive officer of Response Genetics, Inc.
“The capital raised will help support our continued efforts in building a sustainable business of high value genetic tests
for cancer patients as well as a premier pharmaceutical services business. Going forward we will continue to implement additional
operational efficiencies, as evidenced by our improved financial performance relative to the fourth and subsequent quarters of
last year, and will also increase our focus and efforts on growing top line revenue.”

 

The securities sold in
the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not
be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or
an applicable exemption from the registration requirements. Response Genetics, Inc. has agreed to file a registration statement
with the SEC covering the resale of the shares of common stock issued in the private placement. This press release shall not constitute
an offer to sell or the solicitation of an offer to buy Response Genetics, Inc.’s common stock.

 

Thomas A. Bologna, Response Genetic's chairman & chief executive
officer, will present at the UBS 2012 Global Life Sciences Conference taking place at the Grand Hyatt in New York City on Thursday,
September 20, 2012 at 11:00 a.m. ET.

 

Interested investors can access a live webcast of the presentation
by going to the Investor Relations tab on the Response Genetics website: www.responsegenetics.com. A replay of the webcast will
be made available on the company's website for 60 days.

 

    	Page 1 of 2

    	 

    

 

About Response Genetics, Inc.

 

Response Genetics, Inc. (the “Company”) is a CLIA-certified
clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company’s
technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed
and paraffin-embedded specimens. The Company’s principal customers include oncologists and pathologists. In addition to diagnostic
testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of
clinical trial specimens to the pharmaceutical industry. The Company’s headquarters is located in Los Angeles, California.
For more information, please visit www.responsegenetics.com.

 

Forward-Looking Statement Notice

 

Except for the historical information contained herein, this
press release and the statements of representatives of the Company related thereto contain or may contain, among other things,
certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. 

 

Such forward-looking statements involve significant risks
and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives,
projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the
medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and
retain qualified management, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations
with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and
operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic
tests for cancer, the usefulness of genetic information to tailor treatment to patients, successfully consummate
the transactions contemplated by a purchase agreement or to successfully file a registration statement with the SEC, and
other statements identified by words such as “projects,” “may,” “could,” “would,”
“should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans” or similar expressions. 

 

These statements are based upon the current beliefs and expectations
of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s
filings with the SEC. Actual results, including, without limitation, actual sales results, if any, or the application of funds,
may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes
no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except
as required by law. 

 

###

 

    	Page 2 of 2

    	 

    

EXHIBIT E

 

GSK INVESTOR PRESS RELEASE

 

GSK to acquire
five million shares in Response Genetics for US$1.10 per share in cash

 

Issued: XX September
2012, London UK

 

GlaxoSmithKline
plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ:
RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded
share capital of RGI.

 

This transaction
builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI
performs companion diagnostic tests and other related activities for GSK’s immunotherapies and oncology pipeline candidates.

 

GlaxoSmithKline
– one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving
the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit
www.gsk.com.Exhibit 10.2

 

EXECUTION VERSION

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights
Agreement (the “Agreement”) is made and entered into as of this 13th day of September, 2012, by and among Response
Genetics, Inc., a Delaware corporation (the “Company”), and each investor set forth on the signature pages hereto
and any Affiliate or permitted transferee of any such investor who is a subsequent holder of any Registerable Securities (each
an “Investor” and collectively, the “Investors”). Capitalized terms used herein that are
not otherwise defined herein have the respective meanings ascribed to them in the Purchase Agreement, dated as of the date hereof,
by and among the Company and the Persons set forth therein (the “Purchase Agreement”).

 

The parties hereby
agree as follows:

 

1.  Certain
Definitions.

 

As used in this Agreement,
the following terms shall have the following meanings:

 

“Affiliate”
means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries controls, is
controlled by, or is under common control with, such Person. The term “control” (including the terms “controlling,”
“controlled by” and “under common control with”) as used with respect to any Person means
the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such Person,
whether through the ownership of voting securities, by contract or otherwise.

 

“Agreement”
has the meaning ascribed to it in the preambles.

 

“Allowed Delay”
has the meaning ascribed to it in Section 2(d).

 

“Availability
Date” has the meaning ascribed to it in Section 3(k).

 

“Blue Sky
Application” has the meaning ascribed to it in Section 6(a).

 

“Business
Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction
of business.

 

“Closing Date”
has the meaning ascribed to it in Section 2(a).

 

“Common Stock”
means the Company’s common stock, par value $0.01 per share, and any securities into which such shares may hereinafter be
reclassified.

 

“Company”
has the meaning ascribed to it in the preambles.

 

“Cut Back
Shares” has the meaning ascribed to it in Section 2(e).

 

“Effectiveness
Period” has the meaning ascribed to it in Section 3(a).

 

“Filing Deadline”
has the meaning ascribed to it in Section 2(a).

 

“Investor”
or “Investors” have the meaning set forth in the preambles.

 

“Losses”
has the meaning ascribed to it in Section 6(a).

 

“Nasdaq”
means The NASDAQ Capital Market.

 

    	-1-

    	 

    

  

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Piggyback
Registration” has the meaning ascribed to it in Section 2(b).

 

“Prospectus”
means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with
respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by
all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference
or deemed to be incorporated by reference in such prospectus, and (ii) any “free writing prospectus” as defined in
Rule 405 under the 1933 Act.

 

“Purchase
Agreement” has the meaning ascribed to it in the preambles.

 

“Register,”
“registered” and “registration” refer to a registration made by preparing and filing a Registration
Statement or similar document in compliance with the 1933 Act, and the declaration or ordering of effectiveness of such Registration
Statement or document.

 

“Registrable
Securities” means (i) the Shares and (ii) shares of capital stock or any other securities issued or issuable with respect
to or in exchange for the Shares; provided, that, a security shall cease to be a Registrable Security with respect to an Investor
upon (A) sale by such Investor pursuant to a Registration Statement or Rule 144 under the 1933 Act, or (B) such security becoming
eligible for sale by such Investor without restriction by the Investor pursuant to Rule 144(b)(1).

 

“Registration
Statement” means any registration statement of the Company filed under the 1933 Act that covers the resale of any of
the Registrable Securities pursuant to the provisions of this Agreement, amendments and supplements to such Registration Statement,
including post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.

 

“SEC”
means the U.S. Securities and Exchange Commission.

 

“SEC Restrictions”
has the meaning ascribed to it in Section 2(e).

 

“Selling Expenses”
has the meaning ascribed to it in Section 2(c).

 

“Shares”
means the shares of Common Stock issued pursuant to the Purchase Agreement.

 

“Underwritten
Offering” means an offering in which shares of Common Stock are sold to an underwriter on a firm commitment basis for
reoffering to the public or an offering that is a “bought deal” with one or more investment banks.

 

“1933 Act”
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“1934 Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

    	-2-

    	 

    
 

2.          Registration.

 

(a)        Registration
Statements. Promptly following the closing of the purchase and sale of the Shares (the “Closing Date”) but
no later than forty-five (45) days after the Closing Date (the “Filing Deadline”), the Company shall prepare
and file with the SEC one Registration Statement on Form S-3 (or, if Form S-3 is not then available to the Company, on such form
of registration statement as is then available to effect a registration for resale of the Registrable Securities), covering the
resale of the Registrable Securities. Subject to any comments of the SEC staff, such Registration Statement shall include the plan
of distribution attached hereto as Exhibit A; provided, however, that no Investor shall be named as an “underwriter”
in the Registration Statement without such Investor’s prior written consent. Such Registration Statement also shall cover,
to the extent allowable under the 1933 Act and the rules promulgated thereunder (including Rule 416), such indeterminate number
of additional shares of Common Stock resulting from stock splits, stock dividends or similar transactions with respect to the Registrable
Securities. Such Registration Statement shall not include any other shares of Common Stock or other securities for the account
of any other holder without the prior written consent of the Investors. The Registration Statement (and each amendment or supplement
thereto, and each request for acceleration of effectiveness thereof) shall be provided in accordance with Section 3(c) to
each Investor and its counsel prior to its filing or other submission.

 

(b)        Piggyback
Rights.

 

(i)          If
at any time during which there are Registrable Securities outstanding the Company proposes to register any of its common equity
securities under the 1933 Act (other than a registration statement on Form S-8 or on Form S-4 (or any similar successor forms thereto)
or in connection with (A) an employee stock option, stock purchase or compensation plan or securities issued or issuable pursuant
to any such plan, or (B) a dividend reinvestment plan), whether for its own account or for the account of one or more shareholders
of the Company, and the registration form to be used may be used for any registration of Registrable Securities (a “Piggyback
Registration”), the Company shall give prompt written notice (in any event within twenty (20) days after its receipt
of notice of any exercise of other demand registration rights) to each Investor of its intention to effect such a registration
and shall include in such registration all such Registrable Shares with respect to which the Company has received written requests
for inclusion therein within fifteen (15) days after the receipt of the Company’s notice. The Company may postpone or withdraw
the filing or the effectiveness of a Piggyback Registration at any time in its sole discretion.

 

(ii)         If
a Piggyback Registration is an underwritten primary registration on behalf of the Company, and the managing underwriters advise
the Company in writing that in their opinion the number of securities requested to be included in such registration exceeds the
number which can be sold in such offering without having an adverse effect on such offering, the Company shall include in such
registration (i) first, the securities the Company proposes to sell, (ii) second, the Registrable Securities requested to be included
therein by each Investor, and (iii) third, other securities requested to be included in such registration pro rata among the holders
of such securities on the basis of the number of securities requested to be registered by such holders or as such holders may otherwise
agree.

 

    	-3-

    	 

    

 

(iii)        If
a Piggyback Registration is an underwritten secondary registration on behalf of a holder of the Company’s securities other
than Registrable Securities, and the managing underwriters advise the Company in writing that in their opinion the number of securities
requested to be included in such registration exceeds the number which can be sold in such offering without having an adverse effect
on such offering, the Company shall include in such registration (i) first, the securities requested to be included therein by
the holders requesting such registration, (ii) second, the Registrable Securities requested to be included therein by each Investor,
and (iii) third, other securities requested to be included in such registration pro rata among the holders of such securities on
the basis of the number of securities requested to be registered by such holders or as such holders may otherwise agree.

 

(iv)        If
any Piggyback Registration is an underwritten primary offering, the Company shall have the right to select the managing underwriter
or underwriters to administer any such offering.

 

(c)        Expenses.
The Company will pay all expenses associated with each registration, including all registration, filing and securities exchange
listing fees, all word processing, duplicating and printing fees and expenses, the Company’s counsel and accounting fees
and expenses, costs associated with registration, filing, qualification and clearing the Registrable Securities for sale under
applicable state securities laws, Nasdaq listing fees, fees of the Financial Industry Regulatory Authority, transfer taxes and
fees of transfer agents and registrars except for Selling Expenses. Each Investor shall bear its own reasonable fees and expenses
of counsel and such Investor’s reasonable expenses in connection with the registration, including discounts, commissions,
fees of underwriters, selling brokers, dealer managers or similar securities industry professionals with respect to the Registrable
Securities being sold (collectively, the “Selling Expenses”).

 

(d)        Effectiveness.

 

(i)          The
Company shall use commercially reasonable efforts to have the Registration Statement declared effective as soon as practicable
after filing, and in any event no later than the earlier of (i) five (5) Business Days after the SEC staff shall have informed
the Company that no review of the Registration Statement will be made or that the SEC staff has no further comments on the Registration
Statement or (ii) in the case of the Registration Statement filed pursuant to Section 2(a), the 180th day after
the date hereof. The Company shall notify each Investor by facsimile or e-mail as promptly as practicable, and in any event, within
twenty-four (24) hours, after any Registration Statement is declared effective and shall simultaneously provide each Investor with
copies of any related Prospectus to be used in connection with the sale or other disposition of the securities covered thereby.

 

(ii)         For
not more than twenty (20) consecutive days or for a total of not more than forty-five (45) days in any twelve (12)-month period,
the Company may suspend the use of any Prospectus included in any Registration Statement contemplated by this Section 2
in the event that the Company determines in good faith that such suspension is necessary to (A) delay the disclosure of material
non-public information concerning the Company, the disclosure of which at the time is not, in the good faith opinion of the Company,
in the best interests of the Company or (B) amend or supplement the affected Registration Statement or the related Prospectus so
that such Registration Statement or Prospectus shall not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein, in the case of the Prospectus in light of the circumstances
under which they were made, not misleading (an “Allowed Delay”); provided, that the Company shall promptly (a)
notify each Investor in writing of the commencement of and the reasons for an Allowed Delay, but shall not (without the prior written
consent of the Investors) disclose to each Investor any material non-public information giving rise to an Allowed Delay, (b) advise
each Investor in writing to cease all sales under the Registration Statement until the end of the Allowed Delay and (c) use commercially
reasonable efforts to terminate an Allowed Delay as promptly as practicable. Upon disclosure of such information or the termination
of the condition giving rise to the Allowed Delay, the Company shall provide prompt notice to each Investor and shall promptly
terminate any suspension of sales it has put into effect and shall take such other actions to permit registered sales of Registrable
Securities as contemplated in this Agreement.

 

    	-4-

    	 

    

  

(e)        Rule
415; Cutback. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in a
Registration Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the 1933
Act or requires any Investor to be named as an “underwriter”, the Company shall use its commercially reasonable best
efforts to persuade the SEC that the offering contemplated by the Registration Statement is a valid secondary offering and not
an offering “by or on behalf of the issuer” as defined in Rule 415 and that such Investor is not an “underwriter”.
Each Investor shall have the right to participate or have its counsel participate in any meetings or discussions with the SEC regarding
the SEC’s position and to comment or have its counsel comment on and approve any written submission made to the SEC with
respect thereto. No such written submission shall be made to the SEC to which an Investor’s counsel reasonably objects. In
the event that, despite the Company’s commercially reasonable best efforts and compliance with the terms of this Section
2(e), the SEC refuses to alter its position, the Company shall (i) remove from the Registration Statement such portion of the
Registrable Securities (the “Cut Back Shares”) and/or (ii) agree to such restrictions and limitations on the
registration and resale of the Registrable Securities as the SEC may require to assure the Company’s compliance with the
requirements of Rule 415 (collectively, the “SEC Restrictions”); provided, however, that the Company shall not
agree to name any Investor as an “underwriter” in such Registration Statement without the prior written consent of
such Investor. From and after the date on which the SEC Restrictions terminate or expire, all of the provisions of this Section
2 shall again be applicable to the Cut Back Shares.

 

3.    Company
Obligations.  The Company will use reasonable best efforts to effect the registration of the Registrable Securities in accordance
with the terms hereof, and pursuant thereto the Company will, as expeditiously as possible:

 

(a)        use
commercially reasonable efforts to cause a Registration Statement to become effective and to remain continuously effective for
a period that will terminate upon the earlier of (i) the date on which all Registrable Securities covered by such Registration
Statement as amended from time to time, have been sold, (ii) the date on which there are no longer any Registrable Securities outstanding
or (iii) three years from the date of filing of such Registration Statement (the “Effectiveness Period”) and
advise each Investor in writing when the Effectiveness Period has expired;

 

(b)        prepare
and file with the SEC such amendments and post-effective amendments to the Registration Statement and the Prospectus as may be
necessary to keep the Registration Statement effective for the Effectiveness Period and to comply with the provisions of the 1933
Act and the 1934 Act with respect to the distribution of all of the Registrable Securities covered thereby;

 

    	-5-

    	 

    

  

(c)        provide
copies to and permit counsel designated by each Investor to review and comment on each Registration Statement and all amendments
and supplements thereto as far in advance as reasonably practicable but no fewer than seven (7) days prior to their filing with
the SEC and not file any document to which an Investor’s counsel reasonably objects;

 

(d)        furnish
to each Investor and its legal counsel (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or
received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending date, as the case
may be) one (1) copy of any Registration Statement and any amendment thereto, each preliminary prospectus and Prospectus and each
amendment or supplement thereto, and each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and
each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than
any portion of any thereof which contains information for which the Company has sought confidential treatment), and (ii) such number
of copies of a Prospectus, including a preliminary prospectus, and all amendments and supplements thereto and such other documents
as any Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor
that are covered by the related Registration Statement;

 

(e)        use
commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if
such order is issued, obtain the withdrawal of any such order at the earliest possible moment;

 

(f)         prior
to any public offering of Registrable Securities, use commercially reasonable efforts to register or qualify or cooperate with
any Investor, underwriters and their counsel in connection with the registration or qualification of such Registrable Securities
for offer and sale under the securities or blue sky laws of such jurisdictions requested by any Investor and do any and all other
commercially reasonable acts or things necessary or advisable to enable the distribution in such jurisdictions of the Registrable
Securities covered by the Registration Statement; provided, however, that the Company shall not be required in connection therewith
or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify
but for this Section 3(f), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so
subject but for this Section 3(f), or (iii) file a general consent to service of process in any such jurisdiction;

 

(g)        use
commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on Nasdaq
or each securities exchange, interdealer quotation system or other market on which similar securities issued by the Company are
then listed;

 

(h)        immediately
notify each Investor and each underwriter, at any time prior to the end of the Effectiveness Period, upon discovery that, or upon
the happening of any event as a result of which, the Prospectus includes an untrue statement of a material fact or omits to state
any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances
then existing, and promptly prepare, file with the SEC and furnish to such holder a supplement to or an amendment of such Prospectus
as may be necessary so that such Prospectus shall not include an untrue statement of a material fact or omit to state a material
fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then
existing;

 

    	-6-

    	 

    

  

(i)         upon
request, furnish to each Investor copies of any and all transmittal letters or other correspondence with the SEC or any other governmental
agency or self-regulatory body or other body having jurisdiction (including any domestic or foreign securities exchange) relating
to such offering of Registrable Securities;

 

(j)         provide
a transfer agent and registrar for all Registrable Securities covered by such Registration Statement not later than the effective
date of such Registration Statement;

 

(k)        otherwise
use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the 1933 Act and the 1934
Act, including, without limitation, Rule 172 under the 1933 Act (if applicable), file any final Prospectus, including any supplement
or amendment thereof, with the SEC pursuant to Rule 424 under the 1933 Act in order to ensure that it shall not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading, promptly inform each Investor in writing if,
at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result
thereof, each Investor is required to deliver a Prospectus in connection with any disposition of Registrable Securities and take
such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder; and make
available to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below),
an earnings statement covering a period of at least twelve (12) months, beginning after the effective date of each Registration
Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the 1933 Act, including Rule 158 promulgated
thereunder (for the purpose of this Section 3(k), “Availability Date” means the 45th day following the
end of the fourth fiscal quarter that includes the effective date of such Registration Statement, except that, if such fourth fiscal
quarter is the last quarter of the Company’s fiscal year, “Availability Date” means the 90th day after the end
of such fourth fiscal quarter);

 

(l)          with
a view to making available to each Investor the benefits of Rule 144 (or its successor rule) and any other rule or regulation of
the SEC that may at any time permit each Investor to sell shares of Common Stock to the public without registration, covenant and
agree to: (i) make and keep adequate current public information available, as those terms are understood and defined in Rule 144,
until the earlier of (A) six months after such date as all of the Registrable Securities may be sold without restriction by the
holders thereof pursuant to Rule 144 without regard to any volume limitation or current information requirements thereunder or
(B) such date as all of the Registrable Securities shall have been resold; and (ii) furnish to each Investor upon request, as long
as such Investor owns any Registrable Securities, (A) a written statement by the Company that it has complied with the reporting
requirements of the 1934 Act, (B) a copy of the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form
10-Q, and (C) such other information as may be reasonably requested in order to avail such Investor of any rule or regulation of
the SEC that permits the selling of any such Registrable Securities without registration; and

 

    	-7-

    	 

    

  

(m)        take
such other actions as are reasonably requested by each Investor in order to expedite or facilitate the disposition of such Registrable
Securities.

 

4.     Due
Diligence Review; Information. The Company shall make available, during normal business hours, for inspection and review by
any Investor, underwriters, advisors to and representatives of any Investor (who may or may not be affiliated with such Investor
and who are reasonably acceptable to the Company), all financial and other records, and all other corporate documents and properties
of the Company as may be reasonably necessary for the purpose of such review, and cause the Company’s officers, directors
and employees, within a reasonable time period, to supply all such information reasonably requested by any Investor or any such
representative, advisor or underwriter in connection with such Registration Statement (including, without limitation, in response
to all questions and other inquiries reasonably made or submitted by any of them), prior to and from time to time after the filing
and effectiveness of the Registration Statement for the sole purpose of enabling such Investor and such representatives, advisors
and underwriters and their respective accountants and attorneys to conduct initial and ongoing due diligence with respect to the
Company and the accuracy of such Registration Statement.

 

The Company shall not
disclose material nonpublic information to any Investor, or to advisors to or representatives of any Investor, unless prior to
disclosure of such information the Company identifies such information as being material nonpublic information and provides such
Investor, such advisors and representatives with the opportunity to accept or refuse to accept such material nonpublic information
for review and any Investor wishing to obtain such information enters into an appropriate confidentiality agreement with the Company
with respect thereto.

 

5.      Obligations
of the Investors.

 

(a)        Each
Investor shall furnish in writing to the Company such information regarding itself, the Registrable Securities held by it and the
intended method of disposition of the Registrable Securities held by it, as shall be reasonably required to effect the registration
of such Registrable Securities and shall execute such documents in connection with such registration as the Company may reasonably
request. At least five (5) Business Days prior to the first anticipated filing date of any Registration Statement, the Company
shall notify each Investor of the information the Company requires from such Investor if such Investor elects to have any of the
Registrable Securities held by it included in the Registration Statement. Each Investor shall provide such information to the Company
at least two (2) Business Days prior to the first anticipated filing date of such Registration Statement if such Investor elects
to have any of such Registrable Securities included in the Registration Statement.

 

(b)        Each
Investor, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the
Company in connection with the preparation and filing of a Registration Statement hereunder, unless such Investor has notified
the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement.

 

    	-8-

    	 

    

 

(c)        Each
Investor agrees that, upon receipt of any notice from the Company of either (i) the commencement of an Allowed Delay pursuant to
Section 2(c)(ii) or (ii) the happening of an event pursuant to Section 3(h) hereof, such Investor will immediately
discontinue disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities,
until such Investor is advised by the Company in writing that such dispositions may again be made.

 

6.      Indemnification.

 

(a)        Indemnification
by the Company. The Company shall indemnify and hold harmless each Investor and its officers, directors, members, employees
and agents, successors and assigns, and each other person, if any, who controls such Investor within the meaning of the 1933 Act,
against any losses, claims, damages, expenses or liabilities (including reasonable attorneys’ fees and expenses) (collectively,
“Losses”), joint or several, to which they may become subject under the 1933 Act, the 1934 Act or otherwise,
insofar as such Losses (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based
upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any
Registration Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement thereof, or any free writing
prospectus related thereto; (ii) any blue sky application or other document executed by the Company specifically for that purpose
or based upon written information furnished by the Company filed in any state or other jurisdiction in order to qualify any or
all of the Registrable Securities under the securities laws thereof (any such application, document or information herein called
a “Blue Sky Application”); (iii) the omission or alleged omission to state in a Blue Sky Application a material
fact required to be stated therein or necessary to make the statements therein not misleading; (iv) any violation by the Company
or its agents of any rule or regulation promulgated under the 1933 Act or the 1934 Act applicable to the Company or its agents
and relating to action or inaction required of the Company in connection with such registration; or (v) any failure to register
or qualify the Registrable Securities included in any such Registration Statement in any state where the Company or its agents
has affirmatively undertaken or agreed in writing that the Company will undertake such registration or qualification on any Investor’s
behalf and will reimburse such Investor, and each such officer, director or member and each such controlling person for any reasonable
legal or other expenses reasonably incurred by them in connection with investigating or defending any such Loss, action or proceeding;
provided, however, that the Company will not be liable in any such case if and to the extent that any such Loss arises out of or
is based upon (1) an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information
furnished by such Investor or any such controlling person in writing specifically for use in such Registration Statement or Prospectus
or (2) the delivery by such Investor of an outdated or defective Prospectus after the Company has notified such Investor in writing
that the Company does not meet the conditions for use of Rule 172 and that (A) as a result such Investor must deliver a Prospectus
in connection with any sales under the Registration Statement and (B) the Prospectus is outdated or defective and prior to the
receipt by such Investor of an amended or supplemented Prospectus, but only if and to the extent that following the receipt of
the amended or supplemented Prospectus the misstatement or omission giving rise to such loss, claim, damage or liability would
have been corrected.

 

    	-9-

    	 

    

 

(b)        Indemnification
by the Investors. Each Investor shall severally but not jointly indemnify and hold harmless, to the fullest extent permitted
by applicable law, the Company, its directors, officers, employees, stockholders and each person who controls the Company (within
the meaning of the 1933 Act) against any Losses (including reasonable attorney fees) resulting from (x) such Investor’s failure
to deliver a Prospectus in connection with any sales under the Registration Statement after the Company has advised such Investor
in writing that (A) the Company does not meet the conditions for use of Rule 172 and (B) as a result such Investor must deliver
a Prospectus in connection with any sales under the Registration Statement or (y) any untrue statement of a material fact or any
omission of a material fact required to be stated in the Registration Statement or Prospectus or preliminary Prospectus or amendment
or supplement thereto or necessary to make the statements therein not misleading, to the extent, but only to the extent that such
untrue statement or omission is contained in (1) any information furnished in writing by such Investor to the Company specifically
for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto or (2) an outdated or defective Prospectus
delivered by such Investor in connection with any sales under the Registration Statement after the Company has notified such Investor
in writing that the Company does not meet the conditions for use of Rule 172 and that (A) as a result such Investor must deliver
a Prospectus in connection with any sales under the Registration Statement and (B) the Prospectus is outdated or defective and
prior to the receipt by such Investor of an amended or supplemented Prospectus, but only if and to the extent that following the
receipt of the amended or supplemented Prospectus the misstatement or omission giving rise to such loss, claim, damage or liability
would have been corrected. In no event shall the liability of any Investor be greater in amount than the dollar amount of the proceeds
(net of all expense paid by such Investor in connection with any claim relating to this Section 6 and the amount of any
damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received by such Investor
upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification obligation.

 

(c)        Conduct
of Indemnification Proceedings. Any person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying
party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense
of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification
hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses
of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed to pay such fees or expenses,
or (b) the indemnifying party shall have failed to assume the defense of such claim within a reasonable period of time and employ
counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice
of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which
case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense
of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such
person); and provided, further, that the failure of any indemnified party to give notice as provided herein shall not relieve the
indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely
affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall
not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm
of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified
party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation.
No indemnifying party shall be liable for any settlement of any proceeding effected without its written consent, which consent
shall not be unreasonably withheld, but if settled with such consent, or if there be a final judgment for the plaintiff, the indemnifying
party shall indemnify and hold harmless such indemnified party from and against any loss or liability by reason of such settlement
or judgment.

 

    	-10-

    	 

    

  

(d)        Contribution.
If for any reason the indemnification provided for in Sections 6(a) and 6(b) is unavailable to an indemnified party
or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to
the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as
is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant
equitable considerations. No person guilty of fraudulent misrepresentation within the meaning of Section 11(f) of the 1933 Act
shall be entitled to contribution from any person not guilty of such fraudulent misrepresentation. In no event shall the contribution
obligation of a holder of Registrable Securities be greater in amount than the dollar amount of the proceeds (net of all expenses
paid by such holder in connection with any claim relating to this Section 6 and the amount of any damages such holder has
otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by
it upon the sale of the Registrable Securities giving rise to such contribution obligation.

 

(e)        The
indemnification provided for under this Section 6 shall remain in full force and effect regardless of any investigation
made by or on behalf of the indemnified party and shall survive the transfer of securities.

 

(f)         The
provisions of this Section 6 shall be in addition to any other rights to indemnification or contribution which an indemnified
party may have pursuant to law, equity, contract or otherwise.

 

7.      Miscellaneous.

 

(a)        Amendments
and Waivers. This Agreement may be amended only by a writing signed by the Company and each Investor; provided, however, that
no such amendment which adversely affects any Investor shall be binding on such Investor without its written consent. The Company
may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company shall
have obtained the written consent to such action or omission to act, of each Investor; provided, however, that no such action or
omission which disproportionately and materially adversely affects any Investor shall be binding on the Investor without its written
consent.

 

(b)        Notices.
All notices and other communications provided for or permitted hereunder shall be made as set forth in Section 9.4 of the
Purchase Agreement.

 

(c)        Assignments
and Transfers by the Investors. The provisions of this Agreement shall be binding upon and inure to the benefit of each Investor
and its respective successors and assigns. Each Investor may transfer or assign, in whole or from time to time in part, to one
or more persons its rights hereunder in connection with the transfer of Registrable Securities by such Investor to such person,
provided that such Investor complies with all laws applicable thereto and provides written notice of assignment to the Company
promptly after such assignment is effected.

 

    	-11-

    	 

    

  

(d)        Assignments
and Transfers by the Company. This Agreement may not be assigned by the Company (whether by operation of law or otherwise)
without the prior written consent of each Investor, provided, however, that the Company may assign its rights and delegate its
duties hereunder to any surviving or successor corporation in connection with a merger or consolidation of the Company with another
corporation, or a sale, transfer or other disposition of all or substantially all of the Company’s assets to another corporation,
without the prior written consent of the Investors, after notice duly given by the Company to each Investor.

 

(e)        Benefits
of the Agreement. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any
party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement.

 

(f)         Counterparts;
Faxes. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This Agreement may also be executed and transmitted via facsimile, or by
portable document format via electronic mail, which shall be deemed an original.

 

(g)        Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

 

(h)        Severability.
Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted
as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability
in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted
by applicable law, the parties hereby waive any provision of law which renders any provisions hereof prohibited or unenforceable
in any respect.

 

(i)         Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions
as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements
herein contained.

 

(j)         Entire
Agreement. This Agreement, the Purchase Agreement and the schedules and exhibits hereto and thereto are intended by the parties
as a final expression of their agreement and intended to be a complete and exclusive statement of the agreement and understanding
of the parties hereto in respect of the subject matter contained herein and therein. This Agreement, the Purchase Agreement and
the schedules and exhibits hereto and thereto supersede all prior agreements and understandings among the parties with respect
to such subject matter.

 

    	-12-

    	 

    

  

(k)         Governing
Law; Consent to Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed by, and construed in accordance with,
the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably
submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District
Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising
out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or
proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices
under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action
or proceeding and to the laying of venue in such court. Each of the parties hereto irrevocably waives any objection to the laying
of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action
or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT
TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY
AS TO THIS WAIVER.

 

(l)          Specific
Performance. Damages in the event of breach of this Agreement by a party hereto may be difficult, if not impossible, to ascertain,
and it is therefore agreed that each such Person, in addition to and without limiting any other remedy or right it may have, will
have the right to an injunction or other equitable relief in any court of competent jurisdiction, enjoining any such breach, and
enforcing specifically the terms and provisions hereof, and each of the parties hereto hereby waives any and all defenses it may
have on the ground of lack of jurisdiction or competence of the court to grant such an injunction or other equitable relief. The
existence of this right will not preclude any such Person from pursuing any other rights and remedies at law or in equity which
such Person may have.

 

[Signature Pages Follow]

 

    	-13-

    	 

    

 

IN WITNESS WHEREOF,
the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first
above written.

 

	The Company:	RESPONSE GENETICS, INC.
	 	 	 
	 	By:	/s/ Thomas A. Bologna
	 	Name:  	Thomas A. Bologna
	 	Title:	Chairman & Chief Executive Officer

 

[Signature Page – Registration
Rights Agreement]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the
parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above
written.

 

	Investor:	GLAXO GROUP LIMITED
	 	 	 
	 	By:	/s/ Paul Williamson
	 	Name:  	Paul Williamson
	 	Title:	Authorized Signatory
	 	 	For and on behalf of
	 	 	The Wellcome Foundation Limited
	 	 	Corporate Director

 

[Signature Page – Registration
Rights Agreement]

 

    	 

    	 

    

 

 

IN WITNESS WHEREOF,
the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first
above written. 

 

	Investor:	SWIFTCURRENT PARTNERS L.P.
	 	 	 
	 	By:	/s/ Michael Tierney
	 	Name:  	Michael Tierney
	 	Title:	Chief Financial Officer,
	 	 	Bridger Management LLC,
	 	 	Investment Advisor to Swiftcurrent Partners, L.P.

 

	 	SWIFTCURRENT OFFSHORE, LTD.
	 	 	 
	 	By:	/s/ Michael Tierney
	 	Name:  	Michael Tierney
	 	Title:	Chief Financial Officer,
	 	 	Bridger Management LLC,
	 	 	Investment Advisor to Swiftcurrent Offshore, Ltd.

 

[Signature Page – Registration
Rights Agreement] 

 

    	 

    	 

    

 

Exhibit A

 

Plan of Distribution

 

The selling stockholders,
which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests
in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership
distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common
stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices
related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.

 

The selling stockholders
may use any one or more of the following methods when disposing of shares or interests therein:

 

- ordinary brokerage
transactions and transactions in which the broker-dealer solicits purchasers;

 

- one or more block
trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block
as principal to facilitate the transaction;

 

- purchases by a broker-dealer
as principal and resale by the broker-dealer for its account;

 

- an exchange distribution
in accordance with the rules of the applicable exchange;

 

- public or privately
negotiated transactions;

 

- on The NASDAQ Capital
Market (or through the facilities of any national securities exchange or U.S. inter-dealer quotation system of a registered national
securities association, on which the shares are then listed, admitted to unlisted trading privileges or included for quotation);

 

- through underwriters,
brokers or dealers (who may act as agents or principals) or directly to one or more purchasers;

 

- to cover short sales
effected after the date the registration statement of which this Prospectus is a part is declared effective by the SEC;

 

- through the writing
or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

 

- broker-dealers may
agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; and

 

    	 

    	 

    

  

			- a combination of any such methods of sale; and

 

any other method permitted
pursuant to applicable law.

 

In connection with distributions of the
shares or otherwise, the selling stockholders may:

 

		£	enter into hedging transactions with broker-dealers or other financial institutions, which may
in turn engage in short sales of the shares in the course of hedging the positions they assume;

		£	sell the shares short and redeliver the shares to close out such short positions;

		£	enter into option or other transactions with broker-dealers or other financial institutions which
require the delivery to them of shares offered by this prospectus, which they may in turn resell; and

		£	pledge shares to a broker-dealer or other financial institution, which, upon a default, they may
in turn resell.

 

The selling stockholders
may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if
they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of
common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other
successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of
common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling
beneficial owners for purposes of this prospectus.

 

In connection with
the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out
their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling
stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation
of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).

 

The aggregate proceeds
to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less
discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents.
We will not receive any of the proceeds from this offering.

 

The selling stockholders
also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act
of 1933, provided that they meet the criteria and conform to the requirements of that rule.

 

    	 

    	 

    

  

The selling stockholders
and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be "underwriters"
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are "underwriters"
within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.

 

To the extent required,
the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering
prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer
will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.

 

In order to comply
with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered
or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified
for sale or an exemption from registration or qualification requirements is available and is complied with.

 

We have advised the
selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the
market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable we will make
copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the
purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer
that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under
the Securities Act.

 

We have agreed to indemnify
the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating
to the registration of the shares offered by this prospectus.

 

We have agreed with
the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier
of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration
statement or (2) the date on which the shares may be sold without restriction pursuant to Rule 144 of the Securities Act without
regard to any volume limitation requirements thereunder.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]